Oncology Medical News about Docetaxel, Nedaplatin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Second-line combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma
Journal of Thoracic Oncology, 08/14/09

Jin J et al. – In a study to investigate the efficacy and toxicity of the combination of docetaxel followed by nedaplatin as second-line chemotherapy for patients with cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma (ESCC) after surgery, it appears that the combination docetaxel and nedaplatin used in the outpatient setting is well tolerated and useful as second-line chemotherapy for cisplatin-pretreated refractory metastatic/recurrent ESCC.

Methods

This study investigated the efficacy and toxicity of the combination of docetaxel (30 mg/m2) during a 1-hr infusion, followed by nedaplatin (50 mg/m2) during a 2-hr infusion (both drugs were administered on day 1 as an outpatient regimen and repeated every 2 wks) as second-line chemotherapy for pts with cisplatin-pretreated refractory metastatic/recurrent ESCC after surgery.

Results

46 of 48 pts (95.8%) were assessable for response.
Partial response was confirmed in 13 of 48 cases yielding a response rate of 27.1%.
Median overall time to progression and overall survival (OS) was 3.1 mos and 5.9 mos, respectively.
Estimate of OS at 12 mos was 16.7%.
Grade 3 anemia leucopenia, grade 4 anemia leucopenia and neutropenia were detected in only 4 (8.7%), 8 (17.4%), and 9 pts (19.6%), respectively.

<< Previous
cDNA sequencing improves the detection of P53 missense mutations...

Next >>
An overview of coagulation disorders in cancer patients

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
Annals of Oncology, 11/16/09 Relevance Score: 46%

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial
Journal of Clinical Oncology, 11/05/09 Relevance Score: 46%

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09 Relevance Score: 46%

Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09 Relevance Score: 45%

Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
Anti-Cancer Drugs, 10/16/09 Relevance Score: 44%